SGLT-2 Inhibitors May Cut Dementia Risk in Patients With Diabetes
By Lori Solomon HealthDay Reporter
TUESDAY, Sept. 3, 2024 -- Sodium-glucose cotransporter-2 (SGLT-2) inhibitors may prevent dementia in middle-aged adults with diabetes, according to a study published online Aug. 28 in The BMJ.
Anna Shin, from Seoul National University Bundang Hospital in South Korea, and colleagues compared the risk for dementia associated with SGLT-2 inhibitors versus dipeptidyl peptidase-4 (DPP-4) inhibitors in adults (aged 40 to 69 years) with type 2 diabetes. The analysis included 110,885 propensity-matched pairs followed for a mean of 670 days.
The researchers found that the incidence rate for dementia was 0.22 per 100 person-years in initiators of SGLT-2 inhibitors and 0.35 per 100 person-years in initiators of DPP-4 inhibitors (hazard ratios: 0.65 for dementia, 0.54 for dementia requiring drugs, 0.61 for Alzheimer disease, and 0.48 for vascular dementia). Findings persisted regardless of dementia type and across subgroups categorized by age, sex, concomitant use of metformin, and baseline cardiovascular risk. When adjusting for residual confounding (measured by cataract surgery), the risk for dementia remained lower (hazard ratio, 0.70). The association was stronger for treatment of more than two years (hazard ratio, 0.57).
"Highly consistent results over a range of secondary and sensitivity analyses supported the robustness of our study findings," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted September 2024
Read this next
Empagliflozin Has Kidney Protective Effects in Acute Myocardial Infarction
THURSDAY, June 26, 2025 -- Empagliflozin has kidney protective effects and reduces heart failure outcomes across baseline kidney function among patients with acute myocardial...
ADA: Weight Loss, Type 2 Diabetes Remission Up With Replacing Diet Drinks With Water
WEDNESDAY, June 25, 2025 -- For adult women with overweight or obesity and type 2 diabetes (T2D), replacing diet beverages (DBs) with water is associated with greater weight loss...
ADA: Orforglipron Reduces Glycated Hemoglobin in Early Type 2 Diabetes
WEDNESDAY, June 25, 2025 -- The oral small-molecule glucagon-like peptide-1 receptor agonist, orforglipron, reduced glycated hemoglobin (HbA1c) over 40 weeks in adults with early...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.